Cencora (NYSE:COR) Hits New 12-Month High – Should You Buy?

Cencora, Inc. (NYSE:COR) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $369.00 and last traded at $362.6090, with a volume of 1960539 shares trading hands. The stock had previously closed at $365.45.

Analyst Upgrades and Downgrades

Several research analysts have commented on COR shares. TD Cowen raised their price objective on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Evercore ISI set a $400.00 price target on Cencora and gave the stock an “outperform” rating in a research report on Thursday, November 6th. UBS Group lifted their price objective on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. Mizuho upped their price objective on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Finally, Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and an average price target of $371.09.

Cencora Stock Performance

The business has a 50-day moving average of $323.97 and a two-hundred day moving average of $303.25. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The company has a market cap of $70.14 billion, a P/E ratio of 37.22, a P/E/G ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same period in the previous year, the company posted $3.34 earnings per share. The firm’s revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be issued a $0.60 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Cencora’s dividend payout ratio is presently 30.19%.

Insider Buying and Selling at Cencora

In other news, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the sale, the chief executive officer owned 37,940 shares of the company’s stock, valued at $12,398,792. This trade represents a 11.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares in the company, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 41,544 shares of company stock valued at $12,230,941. Company insiders own 10.80% of the company’s stock.

Institutional Trading of Cencora

Institutional investors have recently bought and sold shares of the stock. Atlantic Edge Private Wealth Management LLC raised its holdings in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after buying an additional 35 shares during the last quarter. IAG Wealth Partners LLC purchased a new position in Cencora in the 3rd quarter worth $30,000. Costello Asset Management INC acquired a new stake in Cencora during the 1st quarter worth about $28,000. Cloud Capital Management LLC acquired a new stake in Cencora during the 3rd quarter worth about $31,000. Finally, Caitlin John LLC purchased a new stake in Cencora during the 3rd quarter valued at about $31,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.